At the BIO-Europe Spring Conference in Amsterdam in March 2018, CRA hosted a special program where attendees from biotech, Big Pharma, healthcare provider/payer groups, and patient associations were asked to share their views on pricing strategies for innovative medicine, including cell and gene therapies. More than 60 attendees responded to a series of questions about drug pricing, with a focus on cell and gene therapies, and their responses were captured live through an instantaneous voting system during a panel session.
Their responses highlight the diverse interests and range of opinions about pricing innovative and often high-cost therapies, but also demonstrate that most players in the sector see an urgent need for new pricing models to accommodate these products. The following article, published in BioProcess Online outlines the survey questions and responses from participants in the meeting.
Click here to read the article.
The 3 business models that will attract buyers to my high-cost medical device
The global medical devices market is projected to grow at 4.4% CAGR until 2025. But large medical devices with high initial procurement costs are experiencing...